GLP-1 receptor agonist

NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...

LILLE & PARIS, France, Aug. 4, 2026 4Moving Biotech (4MB) announced the completion of patient enrollment in the Phase...

BAGSVÆRD, Denmark, June 11, 2026 Novo Nordisk announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has...

HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...

BOULDER, Colorado, June 5, 2026 Ambrosia Biosciences has unveiled promising preclinical data for AMB-702, its novel oral small-molecule GLP-1...

INDIANAPOLIS, Indiana, June 7, 2026 Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only...

CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., June 5, 2026 Rivus Pharmaceuticals announced new preclinical data for RV-8451, its...

SAN FRANCISCO, June 5, 2026 Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS...

HONG KONG and NEW ORLEANS, Louisiana, June 8, 2026 Ascletis Pharma has strengthened its position in the highly competitive...

NEW ORLEANS, Louisiana, June 6, 2026 New data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions have...